Dr. Abel joined the Board of Directors in March 2015.  Since 2011, Dr. Abel has served as a business advisor and consultant to companies in the life science sector.  From 2006 to 2011, he served as President and Chief Executive Officer of Immunovaccine, Inc., a clinical-stage biotechnology company developing vaccines against cancer and infectious diseases. 

Dr. Abel is also a former president of Shire Biologics, North American Vaccine, Pasteur Merieux Connaught, and Quadra Logic Technologies, Inc.  His early career was at Bristol Myers and Glaxo Pharmaceuticals.  Dr. Abel has also served as a member of the board of directors for numerous companies, and recently served as Chairman of the Board for Medicago, Inc. until its sale to Mitsubishi Tanabe Pharma Corporation in 2013. 

He currently serves as Chairman of the Board for Medimabs, Inc., a privately-held antibody company.  Dr. Abel attended the Senior Executive Program of the London Business School in the United Kingdom, which holds a bachelor of sciences degree in biochemistry from Bishop's University and a Ph.D. in biochemistry from the Unviersity of British Columbia.  Dr. Abel completed a post doctoral fellowship at the McArdle Cancer Institute of the Unversity of Wisconsin.